Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis

Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been l...

Descripción completa

Detalles Bibliográficos
Autores principales: Benkert, Thomas F., Dietz, Lena, Hartmann, Elena M., Leich, Ellen, Rosenwald, Andreas, Serfling, Edgar, Buttmann, Mathias, Berberich-Siebelt, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527399/
https://www.ncbi.nlm.nih.gov/pubmed/23284936
http://dx.doi.org/10.1371/journal.pone.0052208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527399/
https://www.ncbi.nlm.nih.gov/pubmed/23284936
http://dx.doi.org/10.1371/journal.pone.0052208

Ejemplares similares